Embecta (EMBC) Non-Current Assets (2021 - 2026)
Embecta (EMBC) posted Non-Current Assets of $421.2 million for Q1 2026, down 5.03% sequentially from $443.5 million in Q4 2025, and down 11.66% YoY from $476.8 million in Q1 2025.
Embecta (EMBC) Non-Current Assets (2021 - 2026) Analysis & Trends
Embecta has reported Non-Current Assets for 6 years, with the latest figure at $421.2 million in Q1 2026.
- Quarterly Non-Current Assets fell 11.66% year-over-year to $421.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (down 8.62% YoY) and the FY2025 annual result came in at $459.5 million, down 12.36% from the prior year.
- Non-Current Assets slipped to $421.2 million in Q1 2026 per EMBC's latest filing, from $443.5 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $524.3 million in Q3 2024 and troughed at $407.0 million in Q1 2022.
- A 5-year average of $463.2 million and a median of $465.3 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets slipped 15.01% in 2022, then advanced 14.5% in 2023.
- Over 5 years, Non-Current Assets stood at $435.2 million in 2022, then gained by 14.5% to $498.3 million in 2023, then fell by 3.21% to $482.3 million in 2024, then decreased by 8.04% to $443.5 million in 2025, then fell by 5.03% to $421.2 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $421.2 million, $443.5 million, and $459.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.76 Bn | 129.55 Bn | 1.96 Bn | 11.33 Bn |
| 2 | Becton Dickinson | 52.45 Bn | 51.59 Bn | 2.32 Bn | 42.59 Bn |
| 3 | Alcon | 35.71 Bn | 34.36 Bn | 1.68 Bn | 24.47 Bn |
| 4 | Resmed | 33.91 Bn | 32.44 Bn | 861.22 Mn | 4.64 Bn |
| 5 | Medline | 29.00 Bn | 26.32 Bn | 2.22 Bn | 27.61 Bn |
| 6 | West Pharmaceutical Services | 24.94 Bn | 24.50 Bn | 329.20 Mn | 2.27 Bn |
| 7 | Solventum | 15.30 Bn | 14.89 Bn | 1.29 Bn | 10.50 Bn |
| 8 | Cooper Companies | 14.84 Bn | 14.70 Bn | 735.40 Mn | 10.18 Bn |
| 9 | Baxter International | 13.63 Bn | 11.48 Bn | 1.03 Bn | 12.80 Bn |
| 10 | Embecta | 309.65 Mn | 91.45 Mn | 153.30 Mn | 560.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 560.20 Mn |
| Mar 31, 2026 | 421.20 Mn |
| Dec 31, 2025 | 443.50 Mn |
| Sep 30, 2025 | 459.50 Mn |
| Jun 30, 2025 | 475.80 Mn |
| Mar 31, 2025 | 476.80 Mn |
| Dec 31, 2024 | 482.30 Mn |
| Sep 30, 2024 | 524.30 Mn |
| Jun 30, 2024 | 486.40 Mn |
| Mar 31, 2024 | 489.60 Mn |
| Dec 31, 2023 | 498.30 Mn |
| Sep 30, 2023 | 465.30 Mn |
| Jun 30, 2023 | 464.60 Mn |
| Mar 31, 2023 | 453.70 Mn |
| Dec 31, 2022 | 435.20 Mn |
| Sep 30, 2022 | 421.70 Mn |
| Jun 30, 2022 | 469.20 Mn |
| Mar 31, 2022 | 407.00 Mn |
| Dec 31, 2021 | 481.60 Mn |
| Sep 30, 2021 | 496.20 Mn |